Congenital Gingival Hyperplasia in a Neonate with Foetal Valproate Syndrome

Rodríguez-Vázquez, María; Carrascosa-Romero, M.C.; Pardal-Fernández, José Manuel; Iniesta, Iván

doi:10.1055/s-2007-985901

Cited by 10 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A congenital case has been described in a child exposed to valproic acid in utero. [26] Vigabatrin is a relatively new antiepileptic agent that can also cause gingival overgrowth. Immunohistochemical study suggested that vigabatrin induced an increase in epithelial cell proliferation due to overexpression of antigen Ki-67 and slight underexpression of the CDK-inhibitors p27 KIP1 and p21 WAF1 .…”

Section: Drugs Which Cause Gingival Overgrowthmentioning

confidence: 99%

Drug-induced gingival overgrowth: The nemesis of gingiva unravelled

Bharti¹,

Bansal²

2013

J Indian Soc Periodontol

View full text Add to dashboard Cite

Drug-induced gingival overgrowth or enlargement manifests as abnormal growth of the gingiva due to an adverse drug reaction (ADR) in patients treated with anticonvulsants, immunosuppressants, and calcium channel blockers. As gingival enlargement develops, it affects the normal oral hygiene practice and may interfere with masticatory functions. It gradually becomes a source of pain and the condition often leads to disfiguration. Within the group of patients that develop this unwanted effect, there appears to be variability in the extent and severity of the gingival changes. It would seem pertinent to identify and explore possible risk factors and relating them with the treatment plan. This article throws light on respective drugs and their association with gingival overgrowth and approaches to treatment based on current knowledge and investigative observations.

show abstract

Section: Drugs Which Cause Gingival Overgrowthmentioning

confidence: 99%

Drug-induced gingival overgrowth: The nemesis of gingiva unravelled

Bharti¹,

Bansal²

2013

J Indian Soc Periodontol

View full text Add to dashboard Cite

show abstract

“…Reported cases of gingival enlargements were induced by different drugs; CCBs (50/119 – of which amlodipine-25;[8910111213141516171819202122232425262728] nifedipine-13;[26293031323334353637383940] verapamil-4;[41] felodipine-2;[4243] nisoldipine-1;[44] manidipine-1;[45] and unspecified CCBs-4[46]); phenytoin (11/119);[4748495051525354555657] cyclosporine (31/119);[3546585960616263646566676869707172737475] phenobarbital (4/119);[767778] sodium valproate (3/119 - including one report of congenital drug-induced gingival hyperplasia);[798081] d-penicillamine (2/119);[82] combination oral contraceptive pill-lynestrenol and ethinyl estradiol (1/119);[83] vigabatrin (1/119). [84] Cases of gingival enlargement after combination drug therapy have also been reported; a combination of cyclosporine and CCBs (11/119);[354685...…”

Section: Resultsmentioning

confidence: 99%

Drug-induced gingival overgrowth: A critical insight into case reports from over two decades

Samudrala

Chava

Chandana

et al. 2016

J Indian Soc Periodontol

View full text Add to dashboard Cite

Drug-induced gingival overgrowth (DIGO) is a well-recognized adverse effect of certain systemic medications. Calcium channel blockers, anticonvulsants, and immunosuppressants are frequently implicated drugs in the etiology of DIGO. Drug variables, plaque-induced inflammation, and genetic factors are the three important factors in the expression of gingival changes after systemic medication use. Careful clinical examination and thorough history taking form the basis for diagnosis of DIGO. Histopathological examination is often neglected; however, it is an important aid that helps in differential diagnosis. Cessation or change of drug and meticulous plaque control often leads to regression of the lesion, which however might need surgical correction for optimal maintenance of gingival health. The purpose of the present article is to review case reports and case series published in the last two decades and to assimilate and compile the information for clinical applications such as diagnosis and therapeutic management of DIGO.

show abstract

“…The etiology of the patient's gingival hyperplasia remains unknown. With no family history and no apparent association with any medical syndromes, the impression is that the gingival hyperplasia is idiopathic in nature and possibly exacerbated by some drug influence from divalproex sodium, which has been reported to have controversial effects on gingival tissues [6, 13–16]. It could also be a rare mutation or other hereditary disorder with some variance in expression such that other family members are not affected.…”

Section: Discussionmentioning

confidence: 99%

“…Rare cases of sodium valproate-related gingival enlargement have also been reported, including one involving infantile gingival overgrowth at birth secondary to maternal sodium valproate use [13–16]. However, a clinical study involving epileptic adults receiving sodium valproate and a control group showed no significant differences between the two groups on any parameters assessed [6].…”

Section: Introductionmentioning

confidence: 99%